TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30885194

Group type: EXPERIMENTAL
Intervention: Combined high-intensity interval training (HIIT) with resistance training (RT)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Combined moderate continuous training (MCT) with resistance training (RT)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study: 29173304

Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.6 mg/kg/dose, 2 doses)
Number of subjects: 590

Group type: COMPARATOR
Intervention: Prednisolone/prednisone (1.5 mg/kg/d for 1 day, followed by 1 mg/kg/d on days 2‐5)
Number of subjects: 590
Study: 25537065

Group type: EXPERIMENTAL
Intervention: Sport goggles (G)
Number of subjects: 3

Group type: COMPARATOR
Intervention: No goggles (NG)
Number of subjects: 3
Study: 23599075

Group type: EXPERIMENTAL
Intervention: Low-frequency (1 Hz) 110% motor threshold rTMS for 4 weeks
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sham rTMS for 4 weeks
Number of subjects: 14

Group type: COMPARATOR
Intervention: Comparison of active rTMS vs sham rTMS
Number of subjects: 14
Study: 21349458

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 17393

Group type: COMPARATOR
Intervention: Heparin + glycoprotein IIb/IIIa inhibitor
Number of subjects: 17393

Group type: EXPERIMENTAL
Intervention: Nonaccess site bleeding
Number of subjects: 17393

Group type: EXPERIMENTAL
Intervention: Access site bleeding
Number of subjects: 17393
Study: 19770609

Group type: EXPERIMENTAL
Intervention: Fulfillment of specific items on the Internal Validity Checklist
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Fulfillment of 5 or 6 items on the Internal Validity Checklist
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Higher scores on the Internal Validity Checklist
Number of subjects: 216
Study: 17209059

Group type: EXPERIMENTAL
Intervention: 5-day 2-CdA protocol
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: 6 weekly 2-CdA infusions
Number of subjects: 132
Study: 16942627

Group type: EXPERIMENTAL
Intervention: Physical therapy (PT) twice daily sessions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physical therapy (PT) once daily sessions
Number of subjects: 0
Study: 12940794

Group type: EXPERIMENTAL
Intervention: Decision aid
Number of subjects: 207

Group type: COMPARATOR
Intervention: Pamphlet
Number of subjects: 207
Study: 10679885

Group type: EXPERIMENTAL
Intervention: Standard care plus an educational intervention
Number of subjects: 266

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 266
Study: 8754291

Group type: EXPERIMENTAL
Intervention: Diabetic plasma
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control plasma
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Heat-inactivated diabetic plasma
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zymosan-activated diabetic plasma
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FMLP solution
Number of subjects: 0
Study: 1941404

Group type: EXPERIMENTAL
Intervention: Intravenous bolus infusion of 10% calcium gluconate
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Intravenous bolus infusion of 5% calcium gluconate
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Intravenous bolus infusion of calcium gluconate (both 5% and 10%)
Number of subjects: 36
Study: 7009993

Group type: EXPERIMENTAL
Intervention: Intrapleural BCG immunotherapy
Number of subjects: 169

Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 169
Study: 31629637

Group type: EXPERIMENTAL
Intervention: TachoSil binding suturing technique
Number of subjects: 113

Group type: COMPARATOR
Intervention: Conventional suturing without TachoSil
Number of subjects: 113
Study: 31572763

Group type: EXPERIMENTAL
Intervention: Oral care protocol
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 70
Study: 28407726

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT) plus active Attention Bias Modification Therapy (ABMT)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Cognitive-Behavioral Therapy (CBT) plus placebo Attention Bias Modification Therapy (ABMT)
Number of subjects: 54
Study: 26329852

Group type: EXPERIMENTAL
Intervention: Pre-cooling for 2 min before plain lidocaine injection
Number of subjects: 60

Group type: COMPARATOR
Intervention: Buffered lidocaine injection
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pre-cooling group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Buffered lidocaine group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Pre-cooling and buffered lidocaine
Number of subjects: 60
Study: 24009042

Group type: EXPERIMENTAL
Intervention: Prasugrel (10 mg)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Clopidogrel (75 mg)
Number of subjects: 194
Study: 20972299

Group type: EXPERIMENTAL
Intervention: Short course of antibiotics (48 to 96 hours)
Number of subjects: 52

Group type: COMPARATOR
Intervention: 7-day course of antibiotics
Number of subjects: 52
Study: 19260871

Group type: EXPERIMENTAL
Intervention: FENO guided therapy
Number of subjects: 5

Group type: COMPARATOR
Intervention: Standard asthma therapy
Number of subjects: 5
Study: 17288655

Group type: EXPERIMENTAL
Intervention: Store-and-forward teledermatology
Number of subjects: 508

Group type: COMPARATOR
Intervention: Usual care (conventional clinic-based dermatology appointment)
Number of subjects: 508
Study: 15479681

Group type: EXPERIMENTAL
Intervention: Prebiotic carbohydrates (7.5 g of oligofructose and 7.5 g inulin)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control (no supplement)
Number of subjects: 29
Study: 11777121

Group type: EXPERIMENTAL
Intervention: Individual cognitive-behavioral therapy (CBT)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 63

Group type: COMPARATOR
Intervention: Supportive-expressive group therapy (SEG)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Hamilton Rating Scale for Depression
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Beck Depression Inventory (BDI)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: BDI-18
Number of subjects: 63
Study: 9135184

Group type: EXPERIMENTAL
Intervention: Bimanual cricoid pressure
Number of subjects: 94

Group type: COMPARATOR
Intervention: Single-handed cricoid pressure
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Comparison of both techniques
Number of subjects: 94
Study: 7951548

Group type: EXPERIMENTAL
Intervention: Methimazole (MMI) treatment in untreated patients with low thyroid CT number
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Methimazole (MMI) treatment in patients with normal thyroid CT number prior to therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hyperthyroid Graves' disease
Number of subjects: 60

Group type: COMPARATOR
Intervention: Euthyroid Graves' disease
Number of subjects: 60

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 60
Study: 3038156

Group type: EXPERIMENTAL
Intervention: Oral nafazatrom (Bay g6575, 2 X 3 g)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 31811542

Group type: EXPERIMENTAL
Intervention: Myofunctional therapy support program (MTSP) for 12 weeks
Number of subjects: 31

Group type: COMPARATOR
Intervention: One education session of myofunctional therapy (control)
Number of subjects: 31
Study: 31864351

Group type: EXPERIMENTAL
Intervention: Support packages for adolescent girls on early childbearing
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Randomisation process
Number of subjects: 16
Study: 28051345

Group type: EXPERIMENTAL
Intervention: 4 × 16 min HIIT sessions
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: 4 × 8 min HIIT sessions
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: 4 × 4 min HIIT sessions
Number of subjects: 63
Study: 26103794

Group type: EXPERIMENTAL
Intervention: Telemonitoring group (n = 18)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Usual care group (n = 19)
Number of subjects: 37
Study: 23128579

Group type: EXPERIMENTAL
Intervention: Sensor-augmented pump therapy (SAPT)
Number of subjects: 483

Group type: COMPARATOR
Intervention: Multiple daily injections of insulin (MDI)
Number of subjects: 483
Study: 21982167

Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia with propofol and remifentanil (PR group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Inhalational anesthesia with sevoflurane (S group)
Number of subjects: 40
Study: 19568596

Group type: EXPERIMENTAL
Intervention: Post swim-up acrosome index considered (Group I)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Post swim-up acrosome index not considered (Group II)
Number of subjects: 50
Study: 16924017

Group type: EXPERIMENTAL
Intervention: Children with autism spectrum disorder (ASD)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Children with developmental delay (DD)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Children with typical development (TD)
Number of subjects: 60
Study: 15680096

Group type: EXPERIMENTAL
Intervention: Operative treatment (open reduction and internal fixation using a standard lateral approach)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Nonoperative treatment (ice and elevation)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Operative treatment
Number of subjects: 41

Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 41
Study: 12067850

Group type: EXPERIMENTAL
Intervention: DCA infusion (100 mg/kg body wt)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Hyperoxic breathing (100% O2)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (normoxic breathing and saline infusion)
Number of subjects: 8
Study: 9876731

Group type: EXPERIMENTAL
Intervention: Nizatidine 100 mg intravenously
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 40
Study: 7900703

Group type: EXPERIMENTAL
Intervention: Continuous fluorouracil infusion (FUcont)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Bolus fluorouracil plus leucovorin (FU‐FA)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Quality of life evaluation using linear analogue scales
Number of subjects: 129
Study: 2612552

Group type: EXPERIMENTAL
Intervention: Predictive warfarin maintenance dosing technique
Number of subjects: 43

Group type: COMPARATOR
Intervention: Empirical dosing method
Number of subjects: 43
Study: 863344

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 91

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 91
Study: 31526296

Group type: EXPERIMENTAL
Intervention: E-Course (two 15-minute online classes per week for 3 weeks)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 144
Study: 28187765

Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis patients
Number of subjects: 50
Study: 26381151

Group type: EXPERIMENTAL
Intervention: SBT+SE
Number of subjects: 130

Group type: COMPARATOR
Intervention: SBT
Number of subjects: 130
Study: 23377391

Group type: EXPERIMENTAL
Intervention: MaxClarity
Number of subjects: 40

Group type: COMPARATOR
Intervention: Proactiv
Number of subjects: 40

Group type: COMPARATOR
Intervention: Murad
Number of subjects: 40
Study: 25427324

Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:100000 epinephrine
Number of subjects: 33

Group type: COMPARATOR
Intervention: 2% lidocaine with 1:100000 epinephrine
Number of subjects: 33

Group type: COMPARATOR
Intervention: 2% mepivacaine with 1:100000 epinephrine
Number of subjects: 33
Study: 19154279

Group type: EXPERIMENTAL
Intervention: Progressive addition lenses (PALs) with a near addition of +1.50 D
Number of subjects: 178

Group type: COMPARATOR
Intervention: Single vision (SV) lenses
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Progressive addition lenses (PALs)
Number of subjects: 178
Study: 17157387

Group type: EXPERIMENTAL
Intervention: Good Behavior Game intervention
Number of subjects: 448

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 448
Study: 15340332

Group type: EXPERIMENTAL
Intervention: Active intervention (multifactorial preventive interventions)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Observation (control group)
Number of subjects: 136
Study: 11938803

Group type: EXPERIMENTAL
Intervention: Chinese drugs (CD) for invigorating Spleen to remove dampness, activating blood circulation to eliminate Turbid
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (low protein diet and controlling blood pressure)
Number of subjects: 39
Study: 8941030

Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 1383924

Group type: EXPERIMENTAL
Intervention: MOP chemotherapy
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: MOP followed by radiotherapy (RT)
Number of subjects: 152

Group type: COMPARATOR
Intervention: MOP/ABVD chemotherapy
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Combined modality therapy (CMT)
Number of subjects: 152
Study: 3905463

Group type: EXPERIMENTAL
Intervention: Azathioprine (2 mg/kg) in addition to routine insulin treatment
Number of subjects: 24

Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Treated patients (remission group)
Number of subjects: 24
Study: 31076875

Group type: EXPERIMENTAL
Intervention: Dopamine agonists
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Levodopa
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Anticholinergics
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Initial treatment
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Levodopa equivalent daily dose
Number of subjects: 131
Study: 28651616

Group type: EXPERIMENTAL
Intervention: Dynesys posterior dynamic stabilization (PDS)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Fusion
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: PDS
Number of subjects: 56

Group type: COMPARATOR
Intervention: Both groups (PDS and Fusion)
Number of subjects: 56
Study: 25481367

Group type: EXPERIMENTAL
Intervention: 5 mg/kg caffeine
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Expectancy (response expectancy score)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Caffeine administration (conditional vs deceptive)
Number of subjects: 107
Study: 23560727

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg twice daily for 1 week
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 21493022

Group type: COMPARATOR
Intervention: Estrogen therapy-control (ET-CO)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Placebo-aerobic training (PLA-AT)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Estrogen therapy-aerobic training (ET-AT)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo-control (PLA-CO)
Number of subjects: 47
Study: 19820441

Group type: COMPARATOR
Intervention: Natalizumab induction therapy (12 weeks)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Natalizumab maintenance therapy (48 weeks post-induction)
Number of subjects: 2
Study: 17097449

Group type: EXPERIMENTAL
Intervention: StatLock securing device (experimental group)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Preexisting methods (control group including tape, Velcro strap, CathSecure, or none)
Number of subjects: 118
Study: 14760156

Group type: COMPARATOR
Intervention: ASC only
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: ASC+MVP (mitomycin, vinblastine, and cisplatin)
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: ASC+N (vinorelbine)
Number of subjects: 840
Study: 11497093

Group type: EXPERIMENTAL
Intervention: Mild hypothermia
Number of subjects: 17
Study: 9336321

Group type: EXPERIMENTAL
Intervention: Intranasal cocaine (100 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Combination of alcohol (0.8 g/kg) and cocaine (100 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Combination of alcohol and cocaine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Cocaine alone
Number of subjects: 8
Study: 8402115

Group type: EXPERIMENTAL
Intervention: Reconstruction in the posterior mediastinum
Number of subjects: 96
Study: 2879734

Group type: EXPERIMENTAL
Intervention: Urapidil 15 mg i.v.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Urapidil 30 mg i.v.
Number of subjects: 10

Group type: COMPARATOR
Intervention: Propranolol 5 mg i.v. (positive control)
Number of subjects: 10
Study: 3189211

Group type: EXPERIMENTAL
Intervention: Very-low-calorie diet with 41% protein plus 55% carbohydrate (CD)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Very-low-calorie diet with 95% protein (PP)
Number of subjects: 17
Study: 29313710

Group type: EXPERIMENTAL
Intervention: Nurse-implemented goal-directed sedation protocol
Number of subjects: 1360

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1360
Study: 28399028

Group type: EXPERIMENTAL
Intervention: Laparotomy
Number of subjects: 715

Group type: COMPARATOR
Intervention: Laparoscopy
Number of subjects: 715

Group type: EXPERIMENTAL
Intervention: Adjuvant therapy
Number of subjects: 715

Group type: EXPERIMENTAL
Intervention: High-intermediate risk criteria
Number of subjects: 715

Group type: EXPERIMENTAL
Intervention: High-risk uterine factors
Number of subjects: 715
Study: 26665553

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (1.25 mg/0.05 mL) alone
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Combined treatment (Intravitreal bevacizumab + macular photocoagulation)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Macular photocoagulation alone
Number of subjects: 72
Study: 23201024

Group type: EXPERIMENTAL
Intervention: Retrolisthesis
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control (no retrolisthesis)
Number of subjects: 125
Study: 21638037

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study: 17644263

Group type: EXPERIMENTAL
Intervention: Simultaneous transplantation of Matriderm and split-thickness skin grafting (STSG)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Split-thickness skin grafting (STSG) alone
Number of subjects: 10
Study: 16545672

Group type: EXPERIMENTAL
Intervention: Imagery audiotape intervention used before surgery, after surgery, and after discharge from AS.
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Imagery audiotape intervention
Number of subjects: 75
Study: 12927315

Group type: EXPERIMENTAL
Intervention: estradiol 2 mg/day + cyproterone acetate 1 mg/day in a cyclic sequential regimen
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: estradiol hemihydrate 2 mg/day plus norethisterone acetate (NETA) 1 mg/day in a continuous combined regimen
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: estradiol hemihydrate 1 mg/day plus NETA 0.5 mg/day in a continuous combined regimen
Number of subjects: 41
Study: 11009230

Group type: EXPERIMENTAL
Intervention: Oral mexiletine (up to 900 mg/d)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8725471

Group type: EXPERIMENTAL
Intervention: EGb 761 (160 mg per day in two divided doses)
Number of subjects: 44
Study: 1564114

Group type: EXPERIMENTAL
Intervention: Furlow cleft palate repair using a double opposing Z-plasty
Number of subjects: 10

Group type: COMPARATOR
Intervention: von Langenbeck technique
Number of subjects: 10
Study: 3932215

Group type: EXPERIMENTAL
Intervention: Cefotaxime (CTX)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Clindamycin and gentamicin (C + Gen)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Clindamycin, gentamicin and penicillin (C + Gen + P)
Number of subjects: 46

Group type: COMPARATOR
Intervention: C + Gen
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: All regimens
Number of subjects: 46
Study: 31898055

Group type: EXPERIMENTAL
Intervention: dlPFC tDCS
Number of subjects: 69

Group type: COMPARATOR
Intervention: sham stimulation
Number of subjects: 69
Study: 30519483

Group type: EXPERIMENTAL
Intervention: Multimorbidity exercise rehabilitation
Number of subjects: 17

Group type: COMPARATOR
Intervention: Disease-specific exercise rehabilitation
Number of subjects: 17
Study: 28404110

Group type: EXPERIMENTAL
Intervention: Ombitasvir (25 mg), paritaprevir (150 mg), ritonavir (100 mg) plus weight-based ribavirin for 12 weeks
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Ombitasvir, paritaprevir, ritonavir plus ribavirin for 12 weeks
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Ombitasvir, paritaprevir, ritonavir plus ribavirin for 24 weeks
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Ombitasvir, paritaprevir, ritonavir plus ribavirin
Number of subjects: 160
Study: 24965536

Group type: EXPERIMENTAL
Intervention: Catumaxomab plus prednisolone (25 mg intravenous premedication)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Catumaxomab alone
Number of subjects: 0
Study: 22692377

Group type: EXPERIMENTAL
Intervention: S-ketamine (20 mg/h for 2 h)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: S-ketamine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Rifampicin (pretreatment)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (pretreatment)
Number of subjects: 12
Study: 20307268

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study: 18506154

Group type: COMPARATOR
Intervention: Ezetimibe 10 mg daily (n = 29)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: AEGR-733 5.0 mg daily for the first 4 weeks, 7.5 mg daily for the second 4 weeks, and 10 mg daily for the last 4 weeks (n = 28)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg daily and AEGR-733 with dose titration (n = 28)
Number of subjects: 84
Study: 15919463

Group type: EXPERIMENTAL
Intervention: Tacrolimus (Tacr)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Cyclosporine A (CsA)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Mycophenolate Mofetil (MMF)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Aza (Azathioprine)
Number of subjects: 84
Study: 11451757

Group type: EXPERIMENTAL
Intervention: Trans-diet (9.2 energy percent of trans fatty acids)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Sat-diet (saturated fatty acids)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Trans-diet
Number of subjects: 29

Group type: COMPARATOR
Intervention: Sat-diet
Number of subjects: 29